https://www.live-feeds.com/feed/lilly-snags-another-massachusetts-biotech-as-local-headcount-surges-past-1-400Continuously updated, source-cited coverage. https://www.live-feeds.com/feed/lilly-snags-another-massachusetts-biotech-as-local-headcount-surges-past-1-400https://www.live-feeds.com/feed/lilly-snags-another-massachusetts-biotech-as-local-headcount-surges-past-1-400#u54349Wed, 02 Sep 2026 04:05:08 +0000Eli Lilly has acquired Merida Biosciences for up to $2.875 billion, expanding its autoimmune and allergic disease treatment offerings. The deal adds to Lilly's growing presence in Massachusetts, where its headcount has surged past 1,400. Merida's treatments target rogue antibodies. Lilly aims to advance its immune drug pipeline with this acquisition.Why it mattersThis acquisition is part of Eli Lilly's strategy to bolster its portfolio of autoimmune and allergic disease treatments. The deal reflects Lilly's growing investment in the Massachusetts biotech sector. The acquisi